Person: Nigel Clerkin

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

Shareholder nod for Perrigo Elan deal

US drugmaker Perrigo moved a major step closer to acquiring Dublin-headquartered biotech firm Elan yesterday with shareholders in both companies approving the takeover at separate investor meetings.

business

Elan feels full benefit of Tysabri

business

Elan posts $2.28bn income for Q2, focused on sale

business

Elan seeks to rebuild its asset portfolio

business

Elan chief Martin takes 24% pay cut

business

MS drug Tysabri boosts Elan’s revenue by 11%

Elan revenue up on sales of MS drug

Better-than-expected sales of multiple sclerosis drug Tysabri boosted first-quarter revenue at Irish drug company Elan by 17% to over $288m (€218m).

Fri, 27 Apr, 2012

Elan upbeat despite losses

Pharmaceutical giant Elan today reported a 17% revenue increase resulting in a net loss from continuing operations of $31.8m (€24.08m) in its first-quarter 2012 financial results.

Thu, 26 Apr, 2012

Elan aiming to double its revenue

ELAN is aiming to double its revenues to about $2.5 billion (€1.78bn) and the number of patients using its multiple sclerosis treatment Tysabri over the next five years.

Fri, 28 Oct, 2011

Elan sees 31% growth in Tysabri sales

Pharmaceutical company Elan has seen a 31% growth in sales of its multiple sclerosis drug Tysabri, and a 24% increase in total revenues of $333.5m for the second quarter of this year.

Wed, 27 Jul, 2011

Elan sells Athlone drug unit in $960m cash and equity deal

ELAN has agreed to sell its Athlone, Co Westmeath- based drug delivery unit EDT (Elan Drug Technologies) to US firm Alkermes for nearly $1 billion in a cash and equity deal.

Tue, 10 May, 2011